Home /
News
Stay at the forefront of drug delivery innovation in the contract development and manufacturing organization (CDMO) space. Explore our latest news and announcements, where the demands of today meet the possibilities of tomorrow.
Company announcement
Kindeva Announces Leadership Transition to Drive Strategic Growth
News filter
Meridian Medical Technologies, a Kindeva Drug Delivery company, investing $100+ Million in Bridgeton, Missouri, expansion
St. Louis, Mo. and St. Paul, Minn.; April 11, 2023 (Business Wire) – Meridian Medical Technologies, a Kindeva Drug Delivery Company, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced today, during National Community Development Week, it will expand manufacturing capabilities in Bridgeton, Missouri — investing more than $100 […]
Read moreKindeva Drug Delivery announces the appointment of David Stevens as Global CCO
ST. PAUL, Minn. and ST. LOUIS, Mo.; April 5, 2023 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO). Stevens will spearhead the commercial, business development, and research and […]
Read more
Nutriband with Kindeva Drug Delivery select Aversa™ Fentanyl abuse deterrent formulation for commercial scale manufacturing process development
ORLANDO, Fla., April 4, 2023 – Nutriband Inc.(“Company”) (NASDAQ:NTRB) (NASDAQ:NTRBW) with Kindeva Drug Delivery (“Kindeva”) have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband’s proprietary transdermal abuse deterrent technology which can be […]
Read moreKindeva and Meridian combine: Create leading drug-device combination product CDMO
ST. PAUL, Minn. and ST. LOUIS, Mo.; Dec. 12, 2022 (Business Wire)— Kindeva Drug Delivery (“Kindeva”) and Meridian Medical Technologies (“Meridian”) announced today the completion of the transaction to combine the two companies. The combination has created a leading global contract development and manufacturing organization (“CDMO”) focused on drug-device combination products. The combination will operate […]
Read moreKindeva Drug Delivery and Meridian Medical Technologies to combine
St. Paul, MN (November 14, 2022) — Kindeva Drug Delivery (“Kindeva”) announced today that it will combine with Meridian Medical Technologies (“Meridian”). The combination will create a leading global drug-device combination product Contract Development and Manufacturing Organization (“CDMO”). Kindeva and Meridian will continue to operate independently until closing. The combined company will have a substantial […]
Read moreKindeva Drug Delivery announces collaboration with the Temple University School of Pharmacy
October 13, 2022 Woodbury, MN — Kindeva Drug Delivery LP (Kindeva) has announced a collaboration with the Temple University School of Pharmacy to provide liquid intradermal transdermal system units for the evaluation of nanoparticle-based approaches to overcome tumor drug resistance in rodent models. Jayanth Panyam, professor of pharmaceutical sciences and dean of the Temple University […]
Read moreNutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl
ORLANDO, Fla., September 7, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company’s patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system, with their development and manufacturing partner, Kindeva Drug Delivery. Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating […]
Read moreKindeva Drug Delivery acquisition of iPharma Labs Inc. completed
June 16, 2022 Woodbury, MN — Kindeva Drug Delivery (“Kindeva”) has completed the acquisition of iPharma Labs, Inc. (“iPharma”) located in San Francisco’s Bay Area. This acquisition combines iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing […]
Read moreKindeva Drug Delivery announces collaboration with Synopsys
June 14, 2022 Woodbury, MN — Kindeva Drug Delivery (Kindeva) has announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware™ automated software solutions to assist in creating a state-of-the-art system for accurately measuring Kindeva’s microstructured transdermal system (MTS) arrays. This collaboration will enable fast and accurate measurements of Kindeva’s MTS arrays by […]
Read moreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.